We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01462266
First Posted: October 31, 2011
Last Update Posted: April 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
Results First Submitted: January 8, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin
Drug: Comparator: Placebo
Biological: Insulin Glargine
Drug: Metformin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sitagliptin Sitagliptin 100 mg administered orally once daily for 24 weeks.
Placebo Placebo to sitagliptin administered orally once daily for 24 weeks.

Participant Flow:   Overall Study
    Sitagliptin   Placebo
STARTED   330   330 
Treated   329 [1]   329 [1] 
COMPLETED   295   303 
NOT COMPLETED   35   27 
Adverse Event                7                6 
Death                2                1 
Lack of Efficacy                0                2 
Lost to Follow-up                4                3 
Non-compliance with study drug                3                0 
Creatinine and eGFR, excluded medication                8                4 
Physician Decision                2                5 
Protocol Violation                1                3 
Withdrawal by Subject                7                2 
Screen failure                1                1 
[1] One participant was randomized in error and did not receive study medication.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
One participant in both the Sitagliptin group and Placebo group was randomized in error and did not receive study medication.

Reporting Groups
  Description
Sitagliptin Sitagliptin 100 mg administered orally once daily for 24 weeks.
Placebo Placebo to sitagliptin administered orally once daily for 24 weeks.
Total Total of all reporting groups

Baseline Measures
   Sitagliptin   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 329   329   658 
Age 
[Units: Years]
Mean (Standard Deviation)
 59.3  (8.9)   58.3  (9.7)   58.8  (9.3) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      178  54.1%      165  50.2%      343  52.1% 
Male      151  45.9%      164  49.8%      315  47.9% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Baseline in Daily Insulin Dose at Week 24   [ Time Frame: Baseline and Week 24 ]

2.  Secondary:   Change From Baseline in Hemoglobin A1c (A1C) at Week 24   [ Time Frame: Baseline and Week 24 ]

3.  Secondary:   Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24   [ Time Frame: Baseline and Week 24 ]

4.  Secondary:   Percent of Participants Achieving Fasting Glucose Target at Any Time During the Study   [ Time Frame: Up to 24 weeks ]

5.  Secondary:   Time to Achieve the Fasting Glucose Target   [ Time Frame: Up to 24 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information